Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.

Overview of attention for article published in Drugs of Today = Medicamentos de actualidad, January 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Readers on

mendeley: 24 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,018 followers.

Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. https://t.co/DS1DP8fQ2o

New article: Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. https://t.co/JtSslKzPun #melanoma #oncology

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.